Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
No news?
You could be right.
“..visiting locations..” hahahahahahhahahahhahahhahahahHhhHhahahhahahahhahahhaha
Are people getting it yet?????
Ipix needs more money...what’s new right?
More like zero reason to think that it did.
Happy New Year’s Eve
Did the trial start today ???
Who knows?
End of day might be brutal.
Big pharma working on antivirals. Too little and too late for IPIX imo. Best to go back to running more Phase 2 trials for other conditions. Rinse and repeat.
WHEN will IPIX put any of its compounds into a Phase 3 trial? The most likely answer is never so this saga goes until Leo does exactly what ____?
You fill in the blank.
A) retire
B) step down
C) bankruptcy
D) sell the company
I guess the trial didn’t start this year after all. Bummer.
There’s always next year eh?
Happy early New Year everyone.
Always a reason to not take them into Phase 3.....
Remember: “Diffusion currently intends to participate in two virtual, biopharmaceutical and biotechnology industry conferences in mid-January 2021 – Biotech Showcase and the H.C. Wainwright 2021 Bioconnect Conference – and to provide its next update regarding its development program for TSC at that time.”
Break and old .80 and $1.00 is a target zone.
End of year tax selling ?
Merry Christmas everyone.
Wow. That’s deep.
Supply seems endless
Who is selling ??
I don’t trust much of anything out of Russia.
“From the scientist who helped design the Moderna vaccine, helpful context on new UK strain ??????” Meg Tirrell twitter
From the scientist who helped design the Moderna vaccine, helpful context on new UK strain 👇👇👇 https://t.co/lR0re987o5
— Meg Tirrell (@megtirrell) December 21, 2020
5 year chart. Ug. When does this break $1...then $2
Ugly chart
Post of the day.
Merry Christmas to all the IPIX’ers
FDA GRANTS EMERGENCY USE AUTHORIZATION FOR THE PFIZER VACCINE.
When will the B-Covid Phase 2 trial begin?
Is Alfasigma doing anything with Brilacidin?
LOOK OUT BELOW!!
INNOVATION PHARMACEUTICALS INC.
5,089 Shares of Series B-2 5% Convertible Preferred Stock
Warrants to Purchase Up To 10,178 Shares of Series B-2 5% Convertible Preferred Stock
Probable FDA EUA for Pfizer’s vaccine today.
I am guessing the B Covid P2 will begin in January. Yawn.
Time to drag Kevetrin from the mothball fleet?
Vaccines being administered today and IPIX hasn’t started the Phase 2 trial.
So now let’s talk about the common cold?
Will IPIX participate in either of two virtual biopharmaceutical and biotechnology industry conferences in mid-January 2021?
Biotech Showcase
H.C. Wainwright 2021 Bioconnect Conference
Stare at the shiny object and stop asking for more transparency.
Similar to Brilacidin for Acne
The gig is up. Rabbit holes abound.
Was the real reason the B-ABSSI P3 trial never took place due to incidents of high blood pressure?
A little bird whispered to me that’s what they heard.
Innovation Pharmaceuticals COVID-19 Clinical Trial to Support Additional Development of Brilacidin as a “Pan-Coronavirus” Therapeutic
Company advancing Brilacidin as a next-generation broad-spectrum antiviral for the treatment of common colds and deadly coronavirus infections
WAKEFIELD, MA – November 30, 2020 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announces additional independent preliminary laboratory research suggests Brilacidin, the Company’s flagship defensin mimetic, has the potential to treat other endemic human coronaviruses (H-CoVs), such as those causing common colds, and not just SARS-CoV-2, the novel coronavirus responsible for the ongoing global COVID-19 pandemic.
Research shows Brilacidin exerted potent in vitro inhibition of multiple strains of H-CoVs. On completion of testing, the H-CoV findings are expected to be submitted for peer-review publication. The Company is evaluating these data alongside previously obtained SARS-CoV-2 data, strategizing with its scientific advisors and consultants, to develop Brilacidin as a “pan-coronavirus” therapeutic.
In related news, requisite documentation has been filed with the appropriate regulatory agencies, including an Investigational New Drug application (IND) with the FDA, for conduct of a multinational Phase 2 clinical trial of Brilacidin in patients hospitalized with COVID-19.
Innovation Pharmaceuticals believes Brilacidin is a clearly differentiated leading antiviral drug candidate backstopped by a growing library of laboratory data documenting Brilacidin’s potent ability to inhibit coronaviruses, primarily by disrupting viral integrity and blocking viral entry. The Company is planning to conduct additional in vitro and in vivo Brilacidin studies on multiple coronaviruses, to further inform the drug’s anti-coronavirus properties and prepare for potential future clinical testing.
“Given the alarming recent global spike in COVID-19 cases, coupled with a long-term perspective around the possibility of future pandemics, the appetite for novel anti-coronavirus therapeutics remains strong, as evidenced by Merck paying $425 million in cash last week to acquire OncoImmune to bolster its COVID-19 pipeline,” commented Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. “Early data on vaccines are an encouraging development in combatting the virus. But vaccines have their own challenges—notably, reticence among the public to get vaccinated, combined with delivery obstacles and potential resistance developing due to mutations. Vaccines offer only a partial solution. Major pharma understands this and it is why they are making significant investments in promising COVID-19 therapeutics. The clinical trial of Brilacidin for COVID-19 will be instrumental in taking the first step to develop Brilacidin as a ‘pan-coronavirus’ drug, benefiting patients with illnesses ranging from variants of the common cold to the most serious coronavirus infections.”
Brilacidin and COVID-19
Brilacidin is one of the few drugs targeting COVID-19 that has been tested in human trials (a total of 8) for other clinical indications, providing established safety and efficacy data on over 460 subjects, thereby potentially enabling it to rapidly help address the novel coronavirus crisis. Laboratory testing at independent laboratories supports Brilacidin’s antiviral ability to safely and potently inhibit SARS-CoV-2. In a human lung cell line, Brilacidin achieved a Selectivity Index of 426. A molecular screening study of 11,552 compounds also supports Brilacidin as a promising novel coronavirus treatment. Brilacidin anti-viral research to date has been limited to laboratory-based experiments. Additional pre-clinical and clinical data support Brilacidin’s inhibition of IL-6, IL-1ß, TNF-a and other pro-inflammatory cytokines and chemokines, which have been identified as central drivers in the worsening prognoses of hospitalized COVID-19 patients. Brilacidin’s robust antimicrobial properties might also help to fight secondary bacterial infections, which can co-present in up to 20 percent of COVID-19 patients. Collectively, these data support Brilacidin as a unique 3 in 1 combination—antiviral, immuno/anti-inflammatory, and antimicrobial—COVID-19 therapeutic candidate. A preprint supporting Brilacidin’s COVID-19 treatment potential can be downloaded on bioRxiv.org at the link below.
Brilacidin, a COVID-19 Drug Candidate, Exhibits Potent In Vitro Antiviral Activity Against SARS-CoV-2
https://www.biorxiv.org/content/10.1101/2020.10.29.352450v1.full
Global COVID-19 Cases and Mortality
An online tool tracking COVID-19 cases and mortality, both in the U.S. and globally, can be found on the Company’s website ( http://www.ipharminc.com ), and at the following link:
https://ipixcovid19tracker.com/
Alerts
Sign-up for Innovation Pharmaceuticals email alerts is available at:
http://www.ipharminc.com/email-alerts/
Has anyone asked of heard if IPIX will participate in either of two virtual biopharmaceutical and biotechnology industry conferences in mid-January 2021?
Biotech Showcase
H.C. Wainwright 2021 Bioconnect Conference
Stock price drifting lower.
Nice end of day bounce.
It’s always next year, and be patient.
Who sold out at .60 cents?